CAMBRIDGE, Mass., April 25, 2026 (GLOBE NEWSWIRE) — Implicity, a leader in remote patient monitoring and cardiac data management solutions, today announced the latest findings presented at Heart Rhythm Society (HRS) 2026.
The new HRS data builds on research presented earlier this month at the European Heart Rhythm Association (EHRA) conference, which showed why false positive alerts persist even in modern implantable loop recorders (ILRs). HRS’ follow-up research focused specifically on the latest AI-enabled ILRs, examining whether layering Implicity’s new universal cloud-based AI algorithm on top of the manufacturer’s proprietary algorithms could further reduce false alerts.
In a review of 483 cases from 324 patients using AI-equipped devices, the next-generation ILR ECG analyzer successfully reclassified 61.6% of false-positive alerts into interpretable episodes while maintaining 98.3% sensitivity, reducing clinician workload without compromising patient safety.
“Manufacturer filtering has clearly advanced, whether done in-device, in the cloud, or through a combination of both. But even in these newer systems, residual false-positive alerts remain that continue to burden clinical teams. The findings from our HRS study demonstrate that a manufacturer-independent analysis layer can substantially reduce residual noise while maintaining the high sensitivity needed to protect patient safety,” said Arnaud Rosier, MD, PhD, electrophysiologist, CEO and co-founder of Implicity.
Implicity’s next-generation ILR ECG analyzer is designed to act as an agnostic second layer for residual alerts left after the manufacturer’s initial filters. Implicity’s new universal algorithm works in the cloud and is compatible with all major brands. It applies the most advanced neural networks, drastically reducing the number of false positives without compromising patient safety.
This “dual AI” approach does more than just streamline remote cardiac monitoring workflows; it also reduces alert fatigue by providing clinical teams with highly accurate, reliable data. With more confidence in the data, physicians can spend less time on noise and more time on meaningful cardiac events.
“Newer AI-enabled ILRs provide a cleaner data stream with fewer obvious artifacts, but they are not perfect, and the false positives that remain are often more subtle and clinically ambiguous,” said Niraj Varma, MD, PhD, professor of medicine and consultant electrophysiologist at the Cleveland Clinic. “Those are exactly the alerts that still require careful review. In a remote monitoring workflow, that is extremely important, and any technology that can safely mitigate ILR-related false positive alerts is significant.”
These findings follow evidence presented at EHRA investigate why false positive alerts persist on modern ICM devices. In that work, researchers identified guideline-based interpretation gaps and signal detection problems as key drivers of unactionable alerts. They showed that even on AI-equipped devices, 32.9% of episodes remained unactionable, while another 30.6% were considered indeterminate. Together, the EHRA and HRS analyzes highlight both the mechanisms behind persistent false positives and the potential for a universal, cloud-based AI approach to address them across all devices, including those with or without proprietary AI.
Implicity’s next-generation ILR ECG analyzer algorithm (V2) has not yet been approved by the FDA.
About implied
Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform collects, normalizes and standardizes data from every implantable cardiac device from all manufacturers, improving care for patients with cardiac implants and heart failure.
Implicity’s platform provides critical health information augmented by FDA-cleared AI** algorithms, allowing healthcare providers to make more informed decisions for better patient outcomes while optimizing workflows. With access to the Health Data Hub – a gateway to one of the world’s largest databases of heart disease patients covering almost the entire French heart patient population – Implicity can develop its AI solutions based on more robust data. The company protects more than 110,000 patients in more than 250 medical facilities in the US and Europe. Visit for more information http://www.implicity.com or schedule a meeting with the Implicity team. Contact Daniel Martin, Vice President for US Sales, at daniel.martin@implicity.com or visit booth #1819 at HRS 2026.
Health Data Hub is a health data platform created by the French government to combine existing health patient databases and facilitate their use for research and development purposes
*The version of ILR ECG Analyzer evaluated in this study (V2) has not yet been approved by the FDA. The results may not directly apply to the currently approved version
**SignalHF is an FDA approved Class II medical device, see instructions for use for further information. IM007 ILR ECG Analyzer is an FDA approved Class II medical device and a CE marked Class I medical device (under MDD). See the instructions for use for more information.
IMPLICITY®, Inc. a Delaware corporation with offices located at 185 Alewife Brook Pkwy 210, Cambridge, MA 02138 USA, file number 5917973.
Media contact:
Samantha Choinski
eMedia hub
samantha@emediajunction.com
